Correcting the Hype One Company at a Time

May 30, 2008

In this Forbes Q&A, Matthew Herper interviews James Thomson, who's recently started his own company, Cellular Dynamics International, which is focused on testing experimental drugs for heart side effects. Rather than cave into the hype surrounding regenerative medicine, he sees much bigger opportunities for stem cells as a research tool and in drug discovery.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

UK Bioethics Group Gives Cautious OK for Genetically Modifying Human Embryos

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

CRISPR-Induced Damage?

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

'Fax' It Over

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

This Week in PNAS

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.

Main menu